In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Anti-Cancer Drugs

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00001813-200504000-00008PMID 15746578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies

  2003cited by this paper
• Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt Pathway in Prostate Cancer Cells*

  2003cited by this paper
• Identification of Chelerythrine as an Inhibitor of BclXL Function*

  2003cited by this paper
• Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

  2003cited by this paper
• Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion

  2003cited by this paper
• Ribozyme‐mediated inhibition of PKCα sensitizes androgen‐independent human prostate cancer cells to cisplatin‐induced apoptosis

  2003cited by this paper
• Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)

  2003cited by this paper
• Vitamin A and apoptosis in prostate cancer.

  2002cited by this paper
• Signaling Inhibitors in the Treatment of Prostate Cancer

  2002cited by this paper
• Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.

  2002cited by this paper
• Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro

  2002cited by this paper
• The prospects of retinoids in the treatment of prostate cancer.

  2002cited by this paper
• Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines

  2002cited by this paper
• Modulation of protein kinase C in antitumor treatment.

  2001cited by this paper
• In vitro preclinical models for a rational design of chemotherapy combinations in human tumors.

  2001cited by this paper
• Analysis of recent trends in prostate cancer incidence and mortality

  2000cited by this paper
• Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.

  2000cited by this paper
• Meta‐analysis for combining relative risks of alcohol consumption and prostate cancer

  2000cited by this paper
• Weekly 1‐hour infusion of paclitaxel

  2000cited by this paper
• Carboplatin–paclitaxel‐ and carboplatin–docetaxel‐induced cytotoxic effect in epithelial ovarian carcinoma in vitro

  1999cited by this paper
• Overcoming bcl-2- and p53-mediated resistance in prostate cancer.

  1999cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis.

  1997cited by this paper
• Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.

  1996cited by this paper
• Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy.

  1996cited by this paper
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

  1996cited by this paper
• Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.

  1995cited by this paper
• Carboplatin in advanced hormone refractory prostatic cancer patients.

  1993cited by this paper
• Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.

  1992cited by this paper
• Chelerythrine is a potent and specific inhibitor of protein kinase C.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands.

  1976cited by this paper

• Bidesmosidic betulin saponin bearing L-rhamnopyranoside moieties induces apoptosis and inhibition of lung cancer cells growth in vitro and in vivo

  2018cites this paper
• Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity

  2017cites this paper
• A multi-target protein of hTERTR-FAM96A presents significant anticancer potent in the treatment of hepatocellular carcinoma

  2017cites this paper
• Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

  2017cites this paper
• In vitro cytogenetic evaluation of the particular combination of flurbiprofen and roxithromycin

  2017cites this paper
• Combinations of Alkaloids Affecting Different Molecular Targets with the Saponin Digitonin Can Synergistically Enhance Trypanocidal Activity against Trypanosoma brucei brucei

  2015cites this paper
• Exploring the comparative binding aspects of benzophenanthridine plant alkaloid chelerythrine with RNA triple and double helices: a spectroscopic and calorimetric approach.

  2015cites this paper
• Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity.

  2015cites this paper
• A comparative study on the interaction of the putative anticancer alkaloids, sanguinarine and chelerythrine, with single- and double-stranded, and heat-denatured DNAs

  2015cites this paper
• Induction of self-structure in polyriboadenylic acid by the benzophenanthridine plant alkaloid chelerythrine: a spectroscopic approach

  2014cites this paper
• Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma

  2011cites this paper
• Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

  2010cites this paper
• Distinct G-quadruplex structures of human telomeric DNA formed by the induction of sanguinarine and nitidine under salt-deficient condition.

  2010cites this paper
• Formation of Human Telomeric G-quadruplex Structures Induced by the Quaternary Benzophenanthridine Alkaloids: Sanguinarine, Nitidine, and Chelerythrine

  2010cites this paper
• Biophysical aspects and biological implications of the interaction of benzophenanthridine alkaloids with DNA

  2009cites this paper
• Polymorphic Nucleic Acid Binding of Bioactive Isoquinoline Alkaloids and Their Role in Cancer

  2009cites this paper
• Synthèse et études des relations structure/activité quantitatives (QSAR/2D) d'analyse benzo[c]phénanthridiniques

  2007cites this paper
• Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades

  2007cites this paper
• Verbindungen und Verfahren zur Modulierung von Rho-GTPasen

  2007cites this paper
• Composants et procédés de modulation de Rho GTPases

  2007cites this paper
• DNA-binding affinities and sequence selectivity of quaternary benzophenanthridine alkaloids sanguinarine, chelerythrine, and nitidine.

  2006cites this paper